Russia's Gem-Standard to build one of country's largest plants for blood plasma drugs

3 April 2018

Gem-Standard, one of Russia’s largest producers of drugs on the basis of blood plasma, has invested more than $100 million in the building of a new plant, which is located in the Novoorlovskaya special economic zone in St Petersburg, reports The Pharma Letter’s local correspondent.

According to the company, the annual revenue of the enterprise will be 2.5 billion roubles ($43.5 million), while planned production volume is 500,000 packages per year.

The range of the facility will include blood substitutes, blood clotting factors, intravenous immunoglobulins, human-protein-based substance and some other drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK